L. Welles

发表

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

W. Wilson, S. Steinberg, S. Broder, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

S. Chow, G. Batist, T. Guthrie, 2003, Anti-cancer drugs.

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.

C. Shapiro, D. Hayes, N. Azarnia, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.

E. Winer, C. Hudis, M. Theodoulou, 2009, Clinical breast cancer.

Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies

J. Hainsworth, L. Hart, H. Hochster, 2005 .

A phase I/II trial of liposomal doxorubicin (tlc-d99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (comp) for newly diagnosed intermediate and high grade non-Hodgkin's lymphoma (nhl)

A. Tulpule, A. Levine, W. Boswell, 2001 .

A pilot study of cidofovir in patients with kaposi sarcoma.

S. Pittaluga, D. Whitby, R. Yarchoan, 2003, The Journal of infectious diseases.

Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.

R. Yarchoan, J. Kelley, L. Welles, 2001, Analytical biochemistry.

Activity of thalidomide in AIDS-related Kaposi's sarcoma.

S. Steinberg, J. Goedert, W. Figg, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.

B. Nathwani, A. Tulpule, A. Sherrod, 2006, Clinical lymphoma & myeloma.

Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.

B. Nathwani, A. Tulpule, A. Sherrod, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

G. Batist, P. Chaikin, L. Welles, 2002, Expert opinion on pharmacotherapy.

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Lyndsay Harris, Gerald Batist, E. Winer, 2002, Cancer.